Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Accured Expenses (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Change in Accured Expenses for 5 consecutive years, with $19.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 78.54% year-over-year to $19.6 million, compared with a TTM value of $37.5 million through Dec 2025, down 14.25%, and an annual FY2025 reading of $37.5 million, down 14.25% over the prior year.
  • Change in Accured Expenses was $19.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $8.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $19.6 million in Q4 2025 and bottomed at -$10.6 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is $5.2 million, with a median of $4.7 million recorded in 2022.
  • The sharpest move saw Change in Accured Expenses plummeted 456.87% in 2022, then surged 345.95% in 2023.
  • Year by year, Change in Accured Expenses stood at $10.0 million in 2021, then crashed by 137.74% to -$3.8 million in 2022, then soared by 239.44% to $5.3 million in 2023, then soared by 107.96% to $11.0 million in 2024, then soared by 78.54% to $19.6 million in 2025.
  • Business Quant data shows Change in Accured Expenses for KNSA at $19.6 million in Q4 2025, $8.4 million in Q3 2025, and $13.1 million in Q2 2025.